Shares of Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) dropped 0.1% during trading on Wednesday . The stock traded as low as $8.31 and last traded at $8.40. Approximately 3,005 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 22,076 shares. The stock had previously closed at $8.41.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and issued a $32.00 price target on shares of Surrozen in a research note on Monday, May 12th.
View Our Latest Stock Analysis on SRZN
Surrozen Stock Up 1.2%
The business's 50 day moving average price is $8.50 and its two-hundred day moving average price is $10.29.
Surrozen (NASDAQ:SRZN - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($3.13) EPS for the quarter, missing the consensus estimate of ($1.09) by ($2.04). The company had revenue of $0.98 million for the quarter. Sell-side analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.
Institutional Investors Weigh In On Surrozen
Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in shares of Surrozen by 26.1% in the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company's stock worth $321,000 after purchasing an additional 4,630 shares during the period. Heights Capital Management Inc. bought a new stake in shares of Surrozen in the 1st quarter worth $524,000. Trustees of Columbia University in the City of New York bought a new stake in shares of Surrozen in the 4th quarter worth $688,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Surrozen in the 4th quarter worth $928,000. Finally, Stonepine Capital Management LLC boosted its holdings in shares of Surrozen by 24.7% in the 4th quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company's stock worth $1,969,000 after buying an additional 27,200 shares during the last quarter. 66.57% of the stock is currently owned by institutional investors and hedge funds.
Surrozen Company Profile
(
Get Free Report)
Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Further Reading
Before you consider Surrozen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surrozen wasn't on the list.
While Surrozen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.